Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesPhase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317
Journal of Clinical Oncology, 11/12/09
Gordon MS et al. – Although the RECIST RR of 11% did not exceed prespecified estimates for additional study, single–agent erlotinib yielded disease control and survival outcomes of interest with an expected toxicity profile. The design of future trials of the EGFR axis in pRCC should be based on preclinical or molecular data that define appropriate patient subgroups, new drug combinations, or potentially more active alternative schedules.
Related Articles
The Expression of Thrombospondin-1 and p53 in Clear Cell Renal Cell Carcinoma: Its Relationship to Angiogenesis, Cell Proliferation and Cancer Specific Survival
The Journal of Urology, 10/14/09
Relevance Score: 83%
Outcome after thyroid surgery for metastasis from renal cell cancer
Surgery, 11/03/09
Relevance Score: 81%
Overexpression of myosin VI in prostate cancer cells enhances PSA and VEGF secretion, but has no effect on endocytosis
Oncogene, 10/29/09
Relevance Score: 81%
Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer
Expert Review of Anticancer Therapy, 10/21/09
Relevance Score: 81%
High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth
Clinical Cancer Research, 10/06/09
Relevance Score: 81%
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): A phase II randomised trial
The Lancet Oncology - Online First, 02/09/10
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
Cancer Chemotherapy and Pharmacology, 02/09/10
A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer
Cancer Chemotherapy and Pharmacology, 02/09/10
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Drug Approval Summary: Bevacizumab plus Interferon for Advanced Renal Cell Carcinoma
The Oncologist, 02/09/10
Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death
International Journal of Cancer, 02/09/10
Prevalence of TMPRSS2–ERG and SLC45A3–ERG gene fusions in a large prostatectomy cohort
Modern Pathology, 02/09/10
Article Search
Sponsor
Sponsor